Dr. Reddy's Laboratories Limited has informed the Exchange about Rumour Verification - Regulation 30(11)
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Reddy's Laboratories confirmed a recent CNBC TV18 news item that it is still awaiting approval for its Semaglutide Injection from Health Canada (the 'Notice of Compliance' is yet to come). The company clarified that it has not yet received final regulatory clearance to launch the product in the Canadian market. However, on April 22, 2026, Dr. Reddy's did receive the Drug Identification Numbers (DINs) from Health Canada, which is a step forward in the review process. The company stated it continues to engage constructively with the regulator and is committed to launching the product in Canada once approval is granted. No additional material disclosure is required at this stage.
The clarification is largely neutral — the delay in Canadian approval is now public, but the receipt of DINs signals progress. Short-term sentiment may be mildly cautious given the wait, but no negative financial event or penalty is involved. Shareholders should monitor for the final Notice of Compliance, which would be a positive catalyst for the stock.